Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTaking a planned break from semaglutide is possible, but it carries real consequences that are worth understanding before you stop. Semaglutide works by suppressing appetite and slowing gastric emptying; when you step away from it, both effects fade. Most people find that hunger returns within days to weeks of their last dose, and some regain weight relatively quickly. That said, there are genuine situations where pausing is sensible — illness, surgery, pregnancy planning, or a period where treatment costs are difficult to manage. The key is making that decision with a prescriber, not unilaterally. Wegovy (semaglutide for weight management) is a prescription-only medicine, and stopping or resuming requires clinical review, just as starting did.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide is not a medicine that leaves a lasting change once it clears your system. It reduces hunger while it is active. Stop the injections, and within days that suppression begins to lift. By two to four weeks after your last dose, most people notice appetite back at something close to its pre-treatment baseline.
The longer-term picture is more striking. Extension data from the STEP 1 trial, published in the New England Journal of Medicine, followed participants who stopped semaglutide at 68 weeks. Within a year, they had regained on average about two-thirds of the weight they had lost. That is not a reason to panic, it is a reason to plan. Knowing this in advance is exactly why the decision to pause should not happen in a quiet moment of frustration, or because a bank holiday falls on your usual order day. If the reason is financial, a prescriber can help you think through options.
Weight regain after stopping is not a personal failing. It reflects the biological nature of obesity as a condition, and the fact that semaglutide manages it rather than resolves it. The semaglutide overview on this site covers the mechanism in more detail if you want to understand what changes at a receptor level.
Some reasons to pause are clinically clear-cut. Surgery is one. NHS England advises patients on GLP-1 medicines to tell their surgical and anaesthetic team before any procedure; in some cases, the team will ask you to stop the injection ahead of the operation to reduce aspiration risk. Your prescriber and surgical team make that call together.
Pregnancy planning is another. Semaglutide is not recommended during pregnancy or breastfeeding, and the MHRA advises using contraception while on treatment and for a wash-out period before trying to conceive. If you are thinking about this, our clinical team can talk you through the right timing, you can find more on how nume approaches these conversations on the clinical team page.
Severe illness, particularly anything causing persistent vomiting or significant gut disruption, may also prompt a temporary pause, though in that situation the prescriber needs to know, partly because semaglutide itself can cause nausea, and distinguishing causes matters.
Less clear-cut is a break taken simply because motivation has dipped, or because life has been hectic. That is understandable, but it is worth a conversation before stopping, not after, and our page on whether you can take a break from semaglutide is a good place to start thinking it through. Questions about whether Wegovy is right for you at any given moment are exactly the kind of thing a same-day clinical review is designed to address.
If you and your prescriber agree a break is right, the timing matters. Semaglutide has a half-life of roughly a week, so a single missed dose is not the same as stopping. A deliberate pause means deciding in advance how long, what lifestyle support stays in place during it, and at what point you would restart.
Restarting is not simply a matter of picking up where you left off. Guidance on resuming semaglutide after a gap typically involves going back to a lower dose and re-titrating to reduce gastrointestinal side effects. The length of the gap, your current weight, and any changes in your health since stopping all feed into the prescriber's decision. At nume, every repeat order involves a clinical re-review by a GPhC-registered prescriber; there are no automatic renewals, which means a return after a break gets the same individual attention as an initial consultation.
The NHS patient information for semaglutide notes that missed doses and changes to treatment should be discussed with your prescriber or pharmacist rather than self-managed, and if you are specifically on Wegovy, our guidance on taking a break from Wegovy covers what that process looks like in practice. That guidance stands whether the gap is one week or six months.
One misconception our prescribers encounter fairly regularly is the idea that stopping for a few months and restarting gives you a 'fresh start' on the medicine's effects. There is no strong evidence that a break improves long-term outcomes compared with continuous treatment. The body does not become more or less responsive to semaglutide in a clinically useful way after a short gap.
The framing that tends to help most is this: semaglutide supports weight management while you are taking it. A break is sometimes necessary. But treating it as a strategy in itself (rather than a practical interruption with a plan on either side) is where things tend to go wrong. Explore the broader weight management treatment options available if you are reconsidering whether semaglutide remains the right fit, or speak to a prescriber who can help you weigh up the alternatives.
If you have questions about your specific situation (perhaps you are mid-titration, or you have a holiday coming up and are unsure about storage and timing) speak to our prescribers through a free consultation. A paused treatment plan, reviewed properly, is far safer than one that simply drifts.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.